Research work · 2025

Subcutaneous ivermectin administration in dogs reduces the risk of heartworm diseas

Journal of Veterinary Practice and Health

Abstract

The current study aimed to assess the prevalence of heartworm microfilaria in the blood samples collected from dogs, presented to the Referral Veterinary healthcare institutions in Bhubaneswar city, and to compare the efficacy of heartworm preventives, namely ivermectin through the subcutaneous route, and dermal application of selamectin, in reducing the infection risk in endemic areas. Sixty-five dogs suspected of having microfilaria in their blood, based on clinical signs, were screened for confirmation. Forty-two dogs were found positive by wet blood smear examination. The comparative microfilariacidal efficacy of ivermectin at 50g/µg body weight subcutaneously or selamectin at 10mg/kg body weight as a topical application in reducing transmission risk and public health concern in heartworm endemic areaswas assessed by treating randomly selected 10 positive dogs, divided equally into two groups, II and III, respectively. Five microfilaria-negative dogs served as controls (Group I). The microfilaria load in the blood, counted by methylene blue staining, declined significantly by day 7 following treatment with ivermectin (HitekTM from Virbac Animal Health India), whereas the decline in group III after selamectin (Revolution TM from Pfizer Animal Health Division, New York) dermal application was non-significant (p≥0.05). There was a significant (p<0.05) reduction in total leukocytic counts (TLC) in group II on the 7th and 14th day of treatment, associated with an increase in hemoglobin and PCV. The level of blood urea nitrogen (BUN) and creatinine in group III dogs remained significantly higher than that of the control dogs.

DOI: 10.62184/jvph.jvphj110020253